You are here:

EB lybrido / lybridos

Different Causal Mechanisms for FSIAD: Different Treatments

Based on the assumption that different causal mechanisms are responsible for the same symptoms in FSIAD, we started a drug development program for two subgroups of women. In one subgroup of women sexual dysfunction occurs as the result of a relatively insensitive system for sexual cues. In another subgroup of patients the sexual complaints result from maladaptive sexual inhibitory mechanisms.

Lybrido (working title) has been developed for patients with FSIAD and a relatively insensitive system for sexual cues.

Lybridos (working title) has been developed for women with FSIAD and maladaptive sexual inhibitory mechanisms.

Both drug candidates can be taken ‘on demand’ and help to increase central sexual motivation (libido) about 3 to 6 hours after intake.

Moreover, we have developed an algorithm (simple, practical and useable), based on genetic markers, by which a differentiation can be made between Lybrido and Lybridos responders.